医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GVK BIO Establishes the Largest Isotope Labeling Facility in India

2012年11月19日 PM03:25
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

GVK Biosciences (GVK BIO), Asia’s leading Drug Discovery Research & Development organization, has received approvals from the Atomic Energy Regulatory Board (AERB), Government of India, to carry out 3H and 14C synthesis activities. This GLP compliant facility has state-of-the-art equipment to cater to the requirements of companies engaged in the fields of Drug Discovery and Development, Agro and Veterinary Chemicals, Cosmetics, Perfumery and Specialty Studies.

Speaking of this development, Manni Kantipudi, CEO, GVK BIO, said, “Several of our customers requested us to extend our chemistry services to include isotope labeling services. We listened to our customers and setup this state-of-the art facility which is the largest such facility in India. The facility has received all statutory approvals from the Atomic Energy Review Board of India.

About GVK Biosciences

GVK Biosciences (GVK BIO) is Asia’s leading contract research organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio of nearly 200 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic & research institutions. Please visit us at www.gvkbio.com to know more.

CONTACT

GVK Biosciences Private Limited
Sushant Datta
Dy General
Manager – Corporate Marketing
T 0091 40 66929999
E sushant.datta@gvkbio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates